Organogenesis Holdings Inc. (ORGO)
ORGO Stock Price Chart
Explore Organogenesis Holdings Inc. interactive price chart. Choose custom timeframes to analyze ORGO price movements and trends.
ORGO Company Profile
Discover essential business fundamentals and corporate details for Organogenesis Holdings Inc. (ORGO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
5 Jan 2017
Employees
869.00
Website
https://organogenesis.comCEO
Gary S. Gillheeney
Description
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
ORGO Financial Timeline
Browse a chronological timeline of Organogenesis Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at -$0.09 falling short of the estimated $0.07 by -228.57%, while revenue for the quarter reached $101.01M , missing expectations by -24.68%.
Earnings released on 8 May 2025
EPS came in at -$0.13 falling short of the estimated $0.04 by -425.00%, while revenue for the quarter reached $86.69M , missing expectations by -4.49%.
Earnings released on 27 Feb 2025
EPS came in at $0.04 surpassing the estimated -$0.03 by +233.33%, while revenue for the quarter reached $126.66M , beating expectations by +15.56%.
Earnings released on 12 Nov 2024
EPS came in at $0.09 surpassing the estimated $0.01 by +700.00%, while revenue for the quarter reached $115.18M , beating expectations by +7.71%.
Earnings released on 8 Aug 2024
EPS came in at -$0.13 falling short of the estimated -$0.02 by -550.00%, while revenue for the quarter reached $130.23M , beating expectations by +6.88%.
Earnings released on 9 May 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -25.00%, while revenue for the quarter reached $109.98M , beating expectations by +8.83%.
Earnings released on 29 Feb 2024
EPS came in at -$0.00 falling short of the estimated -$0.00 by -100.47%, while revenue for the quarter reached $99.65M , missing expectations by -8.62%.
Earnings released on 9 Nov 2023
EPS came in at $0.02 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $108.53M , beating expectations by +1.24%.
Earnings released on 9 Aug 2023
EPS came in at $0.04 surpassing the estimated $0.03 by +60.00%, while revenue for the quarter reached $117.32M , beating expectations by +1.93%.
Earnings released on 10 May 2023
EPS came in at -$0.02 matching the estimated -$0.02, while revenue for the quarter reached $107.64M , beating expectations by +12.71%.
Earnings released on 1 Mar 2023
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $115.52M , missing expectations by -5.62%.
Earnings released on 9 Nov 2022
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $116.86M , missing expectations by -3.30%.
Earnings released on 9 Aug 2022
EPS came in at $0.07 falling short of the estimated $0.08 by -12.50%, while revenue for the quarter reached $121.40M , beating expectations by +0.41%.
Earnings released on 10 May 2022
EPS came in at $0.01 falling short of the estimated $0.05 by -80.00%, while revenue for the quarter reached $98.12M , beating expectations by +2.26%.
Earnings released on 1 Mar 2022
EPS came in at $0.39 surpassing the estimated $0.08 by +387.50%, while revenue for the quarter reached $128.56M , beating expectations by +3.08%.
Earnings released on 9 Nov 2021
EPS came in at $0.10 surpassing the estimated $0.06 by +66.67%, while revenue for the quarter reached $113.75M , beating expectations by +0.96%.
Earnings released on 9 Aug 2021
EPS came in at $0.15 surpassing the estimated $0.07 by +114.29%, while revenue for the quarter reached $123.20M , beating expectations by +25.70%.
Earnings released on 10 May 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +400.00%, while revenue for the quarter reached $102.55M , missing expectations by -79.80%.
Earnings released on 16 Mar 2021
EPS came in at $0.15 surpassing the estimated $0.14 by +7.14%, while revenue for the quarter reached $106.81M .
Earnings released on 9 Nov 2020
EPS came in at $0.19 surpassing the estimated -$0.08 by +337.50%, while revenue for the quarter reached $100.80M .
ORGO Stock Performance
Access detailed ORGO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.